Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 30 citing articles:

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15473-15473
Open Access | Times Cited: 49
The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
Ilias D. Vachliotis, Stergios A. Pοlyzos
Current Obesity Reports (2023) Vol. 12, Iss. 3, pp. 191-206
Open Access | Times Cited: 42
Metabolic-Dysfunction Associated Steatotic Liver Disease -Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Ideal Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
(2023)
Open Access | Times Cited: 25
SGLT2 Inhibitors in Kidney Diseases—A Narrative Review
Agata Gajewska, Jakub Wasiak, Natalia Sapeda, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4959-4959
Open Access | Times Cited: 9
Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes
Ito H, Ryota Someya, Takahiro Koyanagi, et al.
Journal of Diabetes Investigation (2025)
Open Access | Times Cited: 1
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Mona Mashayekhi, Bilgunay Ilkin Safa, Matthew S.C. Gonzalez, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 5, pp. 425-438
Closed Access | Times Cited: 8
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Leonardo Buttice, Maryam Ghani, Janahan Suthakar, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2706-2721
Open Access | Times Cited: 8
Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure
Barbora Judita Kasperová, Miloš Mráz, Petr Svoboda, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers
Sul A Lee, Leonardo V. Riella
Kidney International Reports (2024) Vol. 9, Iss. 6, pp. 1601-1613
Open Access | Times Cited: 7
Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
Panagiotis Theofilis, Evangelos Oikonomou, Konstantinos Tsioufis, et al.
Life (2023) Vol. 13, Iss. 2, pp. 497-497
Open Access | Times Cited: 16
The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials
Sepehr Gohari, Faramarz Ismail‐Beigi, Mahsa Mahjani, et al.
BMC Endocrine Disorders (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes
N. Stepanova
Renal Replacement Therapy (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies
Yu Jiang, Guoxiang Zhou, Yongzheng Guo, et al.
Cardiovascular Innovations and Applications (2025) Vol. 9, Iss. 1
Open Access
Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin Following an Admission for Acute Heart Failure
Gema Miñana, Rafael de la Espriella, Miguel Lorenzo, et al.
Cardiorenal Medicine (2025), pp. 1-21
Open Access
Relationship of dietary intake and eating behaviors with glycemic control and body weight under long-term treatment with dapagliflozin: an exploratory prospective study
Hisashi Yokomizo, Daiji Kawanami, Noriyuki Sonoda, et al.
Diabetology International (2025)
Closed Access
The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study
Liana Iordan, Sandra Lazăr, Romulus Timar, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 209-209
Open Access
The real-world anti-inflammatory effect of SGLT2i in patients with chronic heart failure
Alexandru Mircea Arvunescu, Ruxandra Florentina Ionescu, Silviu Ionel Dumitrescu, et al.
Journal of Medicine and Life (2025) Vol. 18, Iss. 2, pp. 155-164
Open Access
Presepsin Levels in Infection-Free Subjects with Diabetes Mellitus: An Exploratory Study
Dimitrios Kouroupis, Ioanna Zografou, Aikaterini Balaska, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 1960-1960
Open Access | Times Cited: 3
The Era of Risk Factors Should End; the Era of Biologic Age Should Begin
Philip D. Houck
Hearts (2025) Vol. 6, Iss. 1, pp. 2-2
Open Access
Insight on Infections in Diabetic Setting
Bianca Pari, Matteo Gallucci, Alberto Ghigo, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 971-971
Open Access | Times Cited: 9
Heart Failure with Preserved Ejection Fraction: The Role of Inflammation
Hongyi Liu, Ruth Magaye, David M. Kaye, et al.
European Journal of Pharmacology (2024) Vol. 980, pp. 176858-176858
Closed Access | Times Cited: 3
Guideline-Optimised Treatment in Heart Failure—Do Higher Doses Reduce Systemic Inflammation More Significantly?
Alexandru Mircea Arvunescu, Ruxandra Florentina Ionescu, Silviu Ionel Dumitrescu, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3056-3056
Open Access | Times Cited: 2
Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes Without Known Heart Failure
Dennis Wang, Anna Naumova, Daniel Isquith, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Veera Ganesh Yerra, Kim A. Connelly
Physiology (2024) Vol. 39, Iss. 6, pp. 412-434
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top